Oberweis Asset Management Inc. acquired a new position in shares of Champions Oncology Inc (NASDAQ:CSBR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 37,233 shares of the biotechnology company’s stock, valued at approximately $291,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in Champions Oncology by 164.3% during the third quarter. Renaissance Technologies LLC now owns 265,846 shares of the biotechnology company’s stock worth $4,644,000 after buying an additional 165,246 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Champions Oncology by 51.4% during the third quarter. Vanguard Group Inc. now owns 231,150 shares of the biotechnology company’s stock worth $4,038,000 after buying an additional 78,428 shares in the last quarter. Vanguard Group Inc boosted its holdings in Champions Oncology by 51.4% during the third quarter. Vanguard Group Inc now owns 231,150 shares of the biotechnology company’s stock worth $4,038,000 after buying an additional 78,428 shares in the last quarter. EAM Investors LLC purchased a new stake in Champions Oncology during the third quarter worth about $3,144,000. Finally, BlackRock Inc. boosted its holdings in Champions Oncology by 1.2% during the fourth quarter. BlackRock Inc. now owns 125,011 shares of the biotechnology company’s stock worth $976,000 after buying an additional 1,471 shares in the last quarter. 52.59% of the stock is currently owned by hedge funds and other institutional investors.

In other Champions Oncology news, CEO Ronnie Morris purchased 20,000 shares of Champions Oncology stock in a transaction on Wednesday, December 19th. The shares were bought at an average price of $7.44 per share, with a total value of $148,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 833,001 shares of the company’s stock, valued at $6,197,527.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. 44.30% of the stock is owned by corporate insiders.

A number of research firms recently commented on CSBR. Zacks Investment Research downgraded shares of Champions Oncology from a “hold” rating to a “strong sell” rating in a report on Friday, December 21st. National Securities began coverage on shares of Champions Oncology in a report on Wednesday, February 27th. They set a “buy” rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $12.75.

CSBR stock opened at $10.13 on Friday. Champions Oncology Inc has a 52 week low of $3.25 and a 52 week high of $17.90. The stock has a market cap of $117.85 million, a P/E ratio of -72.36 and a beta of 1.54. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 0.05.

Champions Oncology (NASDAQ:CSBR) last announced its quarterly earnings results on Monday, December 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). Champions Oncology had a net margin of 0.05% and a return on equity of 1.44%. The business had revenue of $6.69 million during the quarter, compared to analysts’ expectations of $6.35 million. On average, equities analysts predict that Champions Oncology Inc will post 0.12 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Oberweis Asset Management Inc. Takes Position in Champions Oncology Inc (CSBR)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/oberweis-asset-management-inc-takes-position-in-champions-oncology-inc-csbr/2897168.html.

About Champions Oncology

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Further Reading: How does new data get added to a blockchain?

Want to see what other hedge funds are holding CSBR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Champions Oncology Inc (NASDAQ:CSBR).

Institutional Ownership by Quarter for Champions Oncology (NASDAQ:CSBR)

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.